Product image of Metocard (Metoprolol Tartrate) supplied by GNH India

Metocard

Active Ingredient:
Metoprolol Tartrate
Origin:
EU

Metocard (Metoprolol Tartrate)

Metoprolol Tartrate, the active ingredient in Metocard, is a beta‑adrenergic blocking agent presented as an intravenous solution for intravenous administration. It is used to manage hypertension, angina pectoris, acute myocardial infarction and various cardiac arrhythmias in adult patients.

GNH India supplies Metocard as a licensed, Good Distribution Practice‑compliant pharmaceutical product, providing reliable access to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide through its international supply network across multiple regions. All shipments meet EU regulatory standards and are tracked for quality assurance.

Manufacturer / TM Owner

Zaklady Farmaceutyczne Polpharma S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metocard (metoprolol tartrate) is a selective β1‑adrenergic blocker used in cardiovascular disease management.

  • Hypertension: lowers blood pressure by reducing heart rate and cardiac output.
  • Angina pectoris: decreases myocardial oxygen demand, relieving chest pain.
  • Acute myocardial infarction: improves survival by limiting heart workload during the event.
  • Cardiac arrhythmias: stabilises abnormal heart rhythms by slowing conduction through the AV node.

How It Works

  • Metoprolol tartrate selectively antagonises β1‑adrenergic receptors in cardiac tissue, inhibiting the effects of endogenous catecholamines. This reduces heart rate, myocardial contractility, and consequently cardiac output, leading to lower systemic blood pressure and decreased myocardial oxygen consumption.

Side Effects

Metocard may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects

  • Fatigue: feeling unusually tired or weak.
  • Dizziness: light‑headed sensation, especially on standing.
  • Bradycardia: slower than normal heart rate.
  • Cold extremities: reduced blood flow to hands and feet.
  • Headache: mild to moderate pain in the head.
  • Gastrointestinal upset: nausea, abdominal discomfort.

Serious or Rare Side Effects

  • Severe bradycardia: markedly low heart rate requiring medical attention.
  • Hypotension: dangerously low blood pressure.
  • Heart block: impaired electrical conduction in the heart.
  • Bronchospasm: narrowing of airways, especially in patients with asthma.
  • Acute heart failure: sudden worsening of cardiac function.
  • Allergic reactions: rash, swelling, or anaphylaxis.

Precautions & Warnings

When using Metocard, clinicians should consider several safety measures to minimise risk.

  • Renal impairment: adjust dose and monitor kidney function.
  • Asthma or COPD: use with caution as β‑blockade may worsen bronchospasm.
  • Abrupt discontinuation: taper gradually to avoid rebound hypertension.
  • Blood pressure and heart rate: monitor regularly during therapy.
  • Diabetes: be aware that hypoglycemia signs may be masked.
  • Store at room temperature: keep in original container, protect from light and moisture.

Avoid Interactions

Metocard can interact with other medicines, influencing its safety and effectiveness.

Major Interactions (Avoid)

  • Calcium channel blockers (verapamil, diltiazem): may cause excessive bradycardia.
  • Clonidine: abrupt withdrawal can lead to rebound hypertension.
  • Antidiabetic agents: may mask symptoms of low blood sugar.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors: additive blood‑pressure lowering effect.
  • Diuretics: may cause electrolyte disturbances.
  • NSAIDs: can reduce antihypertensive efficacy.

Frequently Asked Questions

Metocard contains metoprolol tartrate, a β1‑adrenergic blocker indicated for hypertension, angina pectoris, acute myocardial infarction, and various cardiac arrhythmias. It is administered intravenously in hospital settings to quickly control heart rate and blood pressure.

Metoprolol tartrate selectively blocks β1‑adrenergic receptors in the heart, reducing the effects of adrenaline and noradrenaline. This leads to a slower heart rate, decreased contractility, and lower cardiac output, which together lower blood pressure and myocardial oxygen demand.

The specific dose of Metocard is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Dosing is individualized and should follow the prescriber’s instructions and local clinical guidelines.

The safety of metoprolol tartrate in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Metocard, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metocard is a selective β1‑blocker, offering cardiac‑specific effects with fewer respiratory side effects compared with non‑selective agents like propranolol. Its intravenous formulation provides rapid onset, which can be advantageous in acute settings such as myocardial infarction or severe hypertension.

Metocard should be stored at room temperature, below 25 °C, in its original packaging. Protect the solution from light and moisture, and keep it out of reach of children. Do not freeze the product.

Metocard is supplied as an intravenous solution and is administered directly into a vein by a qualified healthcare professional. The infusion rate and total dose are determined by the prescriber, and the patient’s vital signs are monitored throughout the administration.

Serious risks include severe bradycardia, marked hypotension, heart block, bronchospasm in patients with reactive airway disease, and rare allergic reactions. Prompt recognition and management of these events are essential, and patients should be monitored closely during therapy.

Metocard is contraindicated in patients with known hypersensitivity to metoprolol or any component of the formulation, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and individuals with uncompensated heart failure or severe asthma/COPD.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metoprolol Tartrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT